GCDFP-15 (23A3) Mouse Monoclonal Antibody
Specialties: Breast/Gynecological Pathology
GCDFP-15 is a 15 kD glycoprotein which is localized in the apocrine metaplastic epithelium lining breast cysts and in apocrine glands in the axilla, vulva, eyelid, ear canal, and in salivary glands.1 GCDFP-15 positivity is seen in breast carcinomas.2,4-6 On the other hand, colorectal carcinomas, lung carcinoma, mesothelimas rarely stain with this antibody.3 Because of its specificity for breast carcinoma, this antibody is often helpful in distinguishing metastasis of unknown primary.4,6-10
- Mazoujian G, et al. Immunohistochemistry of gross cystic disease fluid protein (GCDFP-15) in 65 benign sweat gland tumors of the skin. Am J Dermatopathol. 1988; 10:28-35.
- Ansai S, et al. An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation. Am J Dermatopathol. 1995; 17:249-55.
- Mazoujian G, et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983; 110:105-12.
- Wich MR, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989; 20:281-7.
- Cohen C, et al. Mammary Paget's disease and associated carcinoma. An immunohistochemical study. Arch Pathol Lab Med. 1993; 117:291-4.
- Liegl B, et al. Mammary and extramammary Paget's disease: an immunohistochemical study of 83 cases. Histopathology. 2007; 50:439-47.
- Raju U, et al. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Mod Pathol. 1993; 6:516-20.
- Bhargava R, et al. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007; 127:103-13.
- Tornos C, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005; 29:1482-9.
- Takeda Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008; 132:239-43.
Specifications
- Reactivity: paraffin
- Visualization: cytoplasmic
- Control: breast, breast carcinoma
- Dilution Range: 1:50-1:200*
Package Inserts
IFU
- IVD Rev. 6.0 (CMC25721060)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 25 mL predilute | 257M-10 |
| 0.1 mL concentrate | 257M-14 |
| 0.5 mL concentrate | 257M-15 |
| 1 mL concentrate | 257M-16 |
| 1 mL predilute | 257M-17 |
| 7 mL predilute | 257M-18 |
For in vitro diagnostic (IVD) use in Canada
| 25 mL predilute | 257M-10 |
| 0.1 mL concentrate | 257M-14 |
| 0.5 mL concentrate | 257M-15 |
| 1 mL concentrate | 257M-16 |
| 1 mL predilute | 257M-17 |
| 7 mL predilute | 257M-18 |
For in vitro diagnostic (IVD) use in Europe
| 25 mL predilute | 257M-10 |
| 0.1 mL concentrate | 257M-14 |
| 0.5 mL concentrate | 257M-15 |
| 1 mL concentrate | 257M-16 |
| 1 mL predilute | 257M-17 |
| 7 mL predilute | 257M-18 |
For research use only (RUO) in Japan
| 25 mL predilute | 257M-10-RUO |
| 0.1 mL concentrate | 257M-14-RUO |
| 0.5 mL concentrate | 257M-15-RUO |
| 1 mL concentrate | 257M-16-RUO |
| 1 mL predilute | 257M-17-RUO |
| 7 mL predilute | 257M-18-RUO |
To request information on this product in additional countries, please click the button below.
